Hoth Therapeutics, Inc. Announces the Addition of Dr. Lawrence A. Schachner, M.D. and Dr. Vincent C.O. Njar, Ph.D. to the Company's Scientific Advisory Board

News provided by

Apr 08, 2019, 08:00 ET

NEW YORK, April 8, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and chronic wound disorders, today announced the addition of Dr. Lawrence A. Schachner, M.D. and Dr. Vincent C.O. Njar, Ph.D. to the Company's Scientific Advisory Board. The Scientific Advisory Board was formed to assist the Company in developing the BioLexa Platform and other therapeutics. The BioLexa Platform is a proprietary, patented, drug compound platform developed at the University of Cincinnati.

Lawrence A. Schachner, M.D., is Professor, Former Chair, & Stiefel Laboratories Chair of the Department of Dermatology, Professor of Pediatrics, and Co-Director of the Division of Pediatric Dermatology of the University of Miami Health System. Dr. Schachner has written over 150 scientific publications and is best known as the lead author of the textbook Pediatric Dermatology. In 2004, Dr. Schachner was named "Practitioner of the Year" by the Florida Society of Dermatology and Dermatologic Surgery. The nearly 800 dermatologists in the state lauded him for his longtime commitment to pediatric dermatology. He is past president of the American Society for Pediatric Dermatology and has been cited in numerous periodicals of best doctors, including The Best Doctors in America 1992 to present.

Dr. Schachner has conducted over 40 stage II, III, and IV clinical trials for FDA approval and for post-marketing testing. Dr. Schachner's clinical research has included dermatological products for acne, atopic dermatitis and other eczemas, alopecia areata, vascular tumors (including hemangiomas and malformations) psoriasis, skin infections with bacteria, virus and fungus, scabies and mites, epidermolysis bullosa, bioengineered skin, sun protection, diaper dermatitis children's skin products and pediatric wound healing.

Vincent C. O. Njar, Ph.D. has over 38 years of demonstrated accomplishment as a medicinal chemist and oncopharmacologist in academia at several universities, including 23 years with University of Maryland School of Medicine, Baltimore, MD, USA. He has over 120 scientific publications, over 35 issued patents and 30+ pending patents. He has a Ph.D. in Chemistry from University College In London, UK, and completed a Postdoctoral Fellowship at the Worcester Foundation for Experimental biology in Shrewsbury, Massachusetts.

He is Currently Professor of Medicinal Chemistry and Pharmacology in the Department of Pharmacology at the University of Maryland School of Medicine, Baltimore and Head, Medicinal Chemistry Section, Center for Biomolecular Therapeutics (CBT); Institute for Bioscience and Biotechnology Research (IBBR). He is the Lead Inventor of a drug candidate, galeterone (originally code named VN/124-1), which advanced to Phase III clinical trials in patients with metastatic castration resistant prostate cancer (licensed by UMB to Tokai Pharmaceutical Inc., Boston, MA, USA). Galeterone was recently licensed to Education Scientific LLC (ESL), who is continuing its clinical development. Dr. Njar co-founded Isoprene Pharmaceuticals Inc (IPI) in 2018, a cancer therapeutic company developing novel small molecules for the treatment of cancer.

Mr. Robb Knie, Chief Executive Officer of Hoth Therapeutics, commented, "I am pleased to welcome both Dr. Schachner and Dr. Njar to our Scientific Advisory Board. As we move toward clinical trials, the company is fortunate to have such well respected leaders adding their expertise and insight."

About Hoth Therapeutics, Inc.

Hoth Therapeutics, Inc., a Nevada corporation, is a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema. Hoth has exclusive worldwide rights to the BioLexa Platform.

Forward Looking Statements

This press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements that relate to the advancement and development of the BioLexa Platform, the commencement of clinical trials, the availability of data from clinical trials and other information that is not historical information. When used herein, words such as "anticipate", "being", "will", "plan", "may", "continue", and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Hoth's current expectations and various assumptions. Hoth believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain.

Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described under the caption "Risk Factors" in Hoth's Form 10K for the period ending December 31, 2018, and Hoth's other filings made with the Securities and Exchange Commission. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.

Contact
Investor Relations Contact:
Phone: (646) 756-2997
Email: [email protected]
www.hoththerapeutics.com

SOURCE Hoth Therapeutics, Inc.